Hepatitis C therapy with HCV NS5B polymerase inhibitors

Bibliography

• Soriano V, Labarga P, Fernandez-Montero JV, et al. The changing face of hepatitis C in the new era of direct-acting antivirals. Antivir Res 2013;97:36-40
   PubMed Web of Science ®Google Scholar
• Dabbouseh N, Jensen D. Future therapies for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013; in press
   PubMed Web of Science ®Google Scholar
• Hunt D, Pockros PJ. What are the promising new therapies in the field of chronic hepatitis C after the first-generation direct-acting antivirals? Curr Gastroenterol Rep 2013;15:303-12
   PubMedGoogle Scholar
• Gerber L, Welzel T, Zeuzem S. New therapeutic strategies in HCV: polymerase inhibitors. Liver Int 2013; in press
   PubMed Web of Science ®Google Scholar
• Pockros P. Nucleoside/nucleotide analogue polymerase inhibitors in development. Clin Liver Dis 2013;17:105-10
   PubMed Web of Science ®Google Scholar
• Pockros P. Non-nucleoside analogue polymerase inhibitors in development. Clin Liver Dis 2013;17:123-8
   PubMed Web of Science ®Google Scholar
• Lam A, Espiritu C, Bansal S, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2012;56:3359-68
   PubMed Web of Science ®Google Scholar
• Gane E, Stedman C, Hyland R, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368:34-44
   PubMed Web of Science ®Google Scholar
• Lalezari J, Lawitz E, Rodriguez-Torres M, et al. Once daily PSI-7977 plus peginterferon-ribavirin in a phase IIb trial: rapid virologic suppression in treatment-naïve patients with HCV genotypes 2/3 [abstract 61]. J Hepatol 2011;54(Suppl):28
   Google Scholar
• Lawitz E, Lalezari J, Hassanein T, et al. Once daily PSI-7977 plus peg/RBV in treatment-naïve patients with HCV GT1: robust end of treatment response rates are sustained post-treatment. Hepatology 2011;54:113
   PubMed Web of Science ®Google Scholar
• Lawitz E, Lalezari J, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naïve patients with genotypes 1, 2 and 3 hepatitis C infection: a randomized, double-blind, phase 2 trial. Lancet Infect Dis in press
   Google Scholar
• Kowdley K, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naïve patient with hepatitis C genotype 1 infection (ATOMIC): an open-label, randomized, multicenter phase 2 trial. Lancet 2013; in press
   PubMed Web of Science ®Google Scholar
• Sulkowski M, Gardiner D, Lawitz E, et al. Potent viral suppression with all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (NS5B inhibitor), +/- ribavirin in treatment-naïve patients with chronic HCV GT1, 2 or 3 [abstract LB1422]. J Hepatol 2012;56(Suppl):58
   Google Scholar
• Gane E, Hyland R, Ding X, et al. ELECTRON: 100% suppression of viral load through 4 weeks post-treatment for sofosbuvir + ledipasvir (GS-5885) + ribavirin for 12 weeks in treatment-naïve and –experienced HCV G1 patients [abstract 41LB]. 20th CROI, 3-6 March 2013; Atlanta, GA
   Google Scholar
• Pockros PJ, Jensen D, Tsai N, et al. JUMP-C: a randomized trial of mericitabine plus peginterferon alfa-2a/ribavirin for 24 weeks in treatment-naïve HCV genotypes 1/4 patients. Hepatology 2013; in press
   Google Scholar
• Gane E, Roberts S, Stedman C, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG-7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomized, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010;376:1467-75
   PubMed Web of Science ®Google Scholar
• Gane E, Pockros P, Zeuzem S, et al. Interferon-free treatment with a combination of mericitabine and danoprevir/r with or without ribavirin in treatment-naïve HCV genotype 1 infected patients. J Hepatol 2012;56(Suppl):255
   PubMed Web of Science ®Google Scholar
• Pockros P. Interferon-free hepatitis C therapy. Drugs 2012;72:1825-31
   PubMed Web of Science ®Google Scholar
• Stedman C. Current prospects for interferon-free treatment of hepatitis C in 2012. J Gastroenterol Hepatol 2013;28:38-45
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Asselah T, Angus P, et al. Efficacy of the protease inhibitor BI-201335, polymerase inhibitor BI-207127 and ribavirin in patients with chronic HCV infection. Gastroenterology 2011;141:2047-55
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Asselah T, Angus P, et al. High SVR following IFN-free treatment of chronic HCV GT1 infection for 4 weeks with HCV protease inhibitor in patients with chronic HCV genotype 1 infection, followed by BI-201335 – the SOUND-C1 study [abstract 7A]. Hepatology 2011;54(Suppl):486
   Google Scholar
• Zeuzem S, Soriano V, Asselah T, et al. SVR4 and SVR12 with an interferon-free regimen of BI-201335 and BI-207127 +/- ribavirin in treatment-naïve patients with genotype 1 HCV infection – interim results of SOUND-C2 [abstract 101]. J Hepatol 2012;56(Suppl):54
   Google Scholar
• Jacobson I, Pockros P, Lalezari J, et al. Antiviral activity of filibuvir in combination with pegylated interferon and ribavirin for 28 days in treatment-naïve patients chronically infected with HCV genotype 1. J Hepatol 2009;50(Suppl):382
   Google Scholar
• Nelson D, Gane E, Jacobson I, et al. VX-222/telaprevir in combination with peginterferon and ribavirin in treatment-naïve genotype 1 HCV patients treated for 12 weeks: ZENITH study, SVR12 interim analysis. Hepatology 2011;54(Suppl):1442
   Google Scholar
• Lawitz E, Rodriguez-Torres M, Rustgi V, et al. Safety and antiviral activity of ANA-598 in combination with pegylated interferon plus ribavirin in treatment-naïve genotype 1 chronic HCV patients. J Hepatol 2010;52(Suppl):LB13
   Google Scholar
• Poordad F, Lawitz E, Kowdley K, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013;368:45-53
   PubMed Web of Science ®Google Scholar
• Kowdley K, Lawitz E, Poordad F, et al. 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 and ribavirin achieves SVR12 rates (observed data) of 99% in treatment-naïve patients and 93% in prior null responders with HCV genotype 1 infection. Hepatology 2012;56(Suppl):LB34
   Google Scholar
• King M, Xie W, Larsen L, et al. Risk of virologic relapse in hepatitis C virus GT1-infected subjects after 8, 12, and 24 weeks of ABT-450/r + ABT-267 + ABT-333 + ribavirin: identifying optimal treatment duration [abstract 39]. 20th CROI, 3-6 March 2013; Atlanta, GA
   Google Scholar
• Lawitz E, Poordad F, Kowdley K, et al. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. J Hepatol 2013; in press
   Google Scholar
• Zeuzem S, Buggisch P, Agarwal K, et al. Dual, triple and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin or PEGIFN/RBV for up to 28 days in treatment-naïve genotype 1 HCV subjects. Hepatology 2010;52(Suppl):LB1
   Google Scholar
• Sulkowski M, Rodriguez-Torres M, Lawitz E, et al. High sustained virological response rate in treatment-naïve HCV genotype 1a and 1b patients treated for 12 weeks with an interferon-free all-oral quad regimen: interim results. J Hepatol 2012;56(Suppl):1421
   Google Scholar
• Londoño MC, Lens S, Forns X. Interferon-free regimens for the “difficult to treat”: are we there? J Hepatol 2013; in press
   Web of Science ®Google Scholar
• Soriano V, Vispo E, Poveda E, et al. Treatment failure with new hepatitis C drugs. Expert Opin Pharmacother 2012;13:313-23
   PubMed Web of Science ®Google Scholar
• Treviño A, de Mendoza C, Parra P, et al. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV coinfected patients. Antivir Ther 2011;16:413-16
   PubMed Web of Science ®Google Scholar
• Plaza Z, Soriano V, Gonzalez M, et al. Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV-HCV coinfected patients. J Antimicrob Chemother 2011;66:2838-42
   PubMed Web of Science ®Google Scholar
• Soriano V, Barreiro P, Sherman K. The changing epidemiology of liver disease in HIV patients. AIDS Rev 2013;15:25-31
   PubMed Web of Science ®Google Scholar
• Maring J, Groen H, Wachters F, et al. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J 2005;5:226-43
   PubMed Web of Science ®Google Scholar
• Jiménez-Nácher I, Alvarez E, Morello J, et al. Approaches for understanding and predicting drug interactions in HIV-infected patients. Expert Opin Drug Metab Toxicol 2011;7:457-77
   PubMed Web of Science ®Google Scholar
• Lee M, Yang H, Lu S, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012;206:469-77
   PubMed Web of Science ®Google Scholar
• Martin N, Vickerman P, Foster G, et al. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011;54:1137-44
   PubMed Web of Science ®Google Scholar
• Martin N, Vickerman P, Miners A, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 2012;55:49-57
   PubMed Web of Science ®Google Scholar
• Easterbrook P, Sands A, Harmanci H. Challenges and priorities in the management of HIV/HBV and HIV/HCV coinfection in resource-limited settings. Semin Liver Dis 2012;32:147-57
   PubMed Web of Science ®Google Scholar
• von Schoen-Angerer T, Cohn J, Swan T, Piot P. UNITAID can address HCV/HIV co-infection. Lancet 2013;381:628
   PubMed Web of Science ®Google Scholar